Drugs / UBI Multivalent HIV-1 Peptide Immunogen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00000795 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UBI Multivalent HIV-1 Peptide Immunogen | “A Phase I Safety and Immunogenicity Trial of UBI Multivalent HIV-1 Peptide Immunogen in HIV-1 Seronegative Human Subjects” NCT00000795 ↗ |
| Modality | Vaccine | “a multivalent peptide vaccine has been constructed” NCT00000795 ↗ |